Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,404,148.60 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Simrat Randhawa also recently made the following trade(s):

• On Thursday, March 12th, Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40.

Dianthus Therapeutics Stock Down 1.0%

Shares of NASDAQ DNTH opened at $84.13 on Friday. The business has a fifty day simple moving average of $87.29 and a two-hundred day simple moving average of $63.58. The firm has a market cap of $4.60 billion, a PE ratio of -20.37 and a beta of 1.18. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares during the last quarter. American Century Companies Inc. grew its stake in Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after buying an additional 6,323 shares during the last quarter. Invesco Ltd. grew its stake in Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after buying an additional 4,962 shares during the last quarter. Alliancebernstein L.P. grew its stake in Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after buying an additional 149,200 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics during the 2nd quarter worth $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on DNTH shares. William Blair reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Oppenheimer boosted their price target on Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Stifel Nicolaus set a $120.00 price target on Dianthus Therapeutics in a research report on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Buy” and an average price target of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.